Compare Stocks: CADL, QURE, CLDX, and RCUS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.84 -4.5%	$11.27	$4.35 ▼ $14.00	$867.72M	-0.48	1.10 million shs	3.01 million shs
CLDX Celldex Therapeutics	$38.24 -1.9%	$39.13	$22.10 ▼ $45.14	$3.06B	0.84	657,091 shs	2.08 million shs
QURE uniQure	$44.00 -0.2%	$44.46	$8.73 ▼ $71.50	$3.06B	0.94	1.13 million shs	2.10 million shs
RCUS Arcus Biosciences	$25.30 -1.0%	$28.40	$12.11 ▼ $31.74	$3.25B	0.81	1.43 million shs	2.90 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	-4.45%	+2.70%	-19.74%	+30.39%	+123.86%
CLDX Celldex Therapeutics	-1.90%	+3.63%	-8.30%	+17.92%	+56.34%
QURE uniQure	-0.20%	-1.15%	-9.76%	-4.95%	+210.73%
RCUS Arcus Biosciences	-1.23%	+2.73%	-16.50%	+3.72%	+110.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.84 -4.5%	$11.27	$4.35 ▼ $14.00	$867.72M	-0.48	1.10 million shs	3.01 million shs
CLDX Celldex Therapeutics	$38.24 -1.9%	$39.13	$22.10 ▼ $45.14	$3.06B	0.84	657,091 shs	2.08 million shs
QURE uniQure	$44.00 -0.2%	$44.46	$8.73 ▼ $71.50	$3.06B	0.94	1.13 million shs	2.10 million shs
RCUS Arcus Biosciences	$25.30 -1.0%	$28.40	$12.11 ▼ $31.74	$3.25B	0.81	1.43 million shs	2.90 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	-4.45%	+2.70%	-19.74%	+30.39%	+123.86%
CLDX Celldex Therapeutics	-1.90%	+3.63%	-8.30%	+17.92%	+56.34%
QURE uniQure	-0.20%	-1.15%	-9.76%	-4.95%	+210.73%
RCUS Arcus Biosciences	-1.23%	+2.73%	-16.50%	+3.72%	+110.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	2.64	Moderate Buy	$19.29	77.99% Upside
CLDX Celldex Therapeutics	2.85	Moderate Buy	$56.42	47.53% Upside
QURE uniQure	2.76	Moderate Buy	$65.00	47.73% Upside
RCUS Arcus Biosciences	2.64	Moderate Buy	$38.30	51.40% Upside

Current Analyst Ratings Breakdown

Latest CADL, QURE, CLDX, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	RCUS Arcus Biosciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/11/2026	RCUS Arcus Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/10/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$46.00 ➝ $50.00
9/8/2026	RCUS Arcus Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00 ➝ $40.00
9/2/2026	QURE uniQure	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Outperform
8/17/2026	CADL Candel Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$9.00 ➝ $12.00
8/13/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
8/10/2026	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$23.00
8/7/2026	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
CLDX Celldex Therapeutics	$1.54M	1,949.99	N/A	N/A	$7.93 per share	4.82
QURE uniQure	$18.67M	163.46	N/A	N/A	$3.19 per share	13.79
RCUS Arcus Biosciences	$247M	13.04	N/A	N/A	$5.84 per share	4.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$38.18M	-$1.41	N/A	N/A	N/A	N/A	-76.98%	-48.50%	11/12/2026 (Estimated)
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
QURE uniQure	-$198.97M	-$4.01	N/A	N/A	N/A	-1,350.73%	-111.96%	-29.01%	11/9/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)

Latest CADL, QURE, CLDX, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.2379	-$0.52	-$0.2821	-$0.52	N/A	N/A
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million
7/29/2026	Q2 2026	QURE uniQure	-$0.8223	-$1.22	-$0.3977	-$1.22	$5.45 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.38	16.09	16.09
CLDX Celldex Therapeutics	N/A	11.82	11.82
QURE uniQure	0.15	10.01	10.01
RCUS Arcus Biosciences	0.22	3.82	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
CLDX Celldex Therapeutics	N/A
QURE uniQure	78.83%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	14.30%
CLDX Celldex Therapeutics	5.20%
QURE uniQure	4.65%
RCUS Arcus Biosciences	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	55	76.52 million	65.58 million	Optionable
CLDX Celldex Therapeutics	198	78.53 million	74.45 million	Optionable
QURE uniQure	221	69.37 million	66.14 million	Optionable
RCUS Arcus Biosciences	601	127.33 million	117.66 million	Optionable

CADL, QURE, CLDX, and RCUS Headlines

Recent News About These Companies

TD Cowen Initiates Arcus Biosciences at Buy

September 16 at 7:16 AM | marketscreener.comM

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 16 at 2:15 AM | americanbankingnews.com

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Moderate Buy" from Analysts

September 16 at 2:13 AM | marketbeat.com

Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Arcus Biosciences (NYSE:RCUS) Shares Down 5.6% - Here's What Happened

September 11, 2026 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

September 9, 2026 | businesswire.com

Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Allianz Asset Management GmbH Purchases New Stake in Arcus Biosciences, Inc. $RCUS

September 9, 2026 | marketbeat.com

42,338 Shares in Arcus Biosciences, Inc. $RCUS Acquired by Jupiter Topco LLC

September 5, 2026 | marketbeat.com

Arcus Biosciences Advances Casdatifan With New Liver Function Study

September 4, 2026 | tipranks.com

The Manufacturers Life Insurance Company Makes New $1.41 Million Investment in Arcus Biosciences, Inc. $RCUS

September 4, 2026 | marketbeat.com

Legal & General Group Plc Invests $5.91 Million in Arcus Biosciences, Inc. $RCUS

September 4, 2026 | marketbeat.com

Corient Private Wealth LP Invests $1.82 Million in Arcus Biosciences, Inc. $RCUS

September 4, 2026 | marketbeat.com

Arcus Biosciences, Inc. $RCUS Position Decreased by Montanova Capital LLC

September 1, 2026 | marketbeat.com

Wellington Management Group LLP Sells 194,068 Shares of Arcus Biosciences, Inc. $RCUS

September 1, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $16.74 Million in Arcus Biosciences, Inc. $RCUS

September 1, 2026 | marketbeat.com

Man Group plc Acquires New Shares in Arcus Biosciences, Inc. $RCUS

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Arcus Biosciences, Inc. $RCUS

August 27, 2026 | marketbeat.com

Deutsche Bank AG Invests $2.92 Million in Arcus Biosciences, Inc. $RCUS

August 27, 2026 | marketbeat.com

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

August 26, 2026 | businesswire.com

Odyssean LLC Makes New Investment in Arcus Biosciences, Inc. $RCUS

August 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL, QURE, CLDX, and RCUS Company Descriptions

Candel Therapeutics NASDAQ:CADL

$10.84 -0.51 (-4.45%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$10.84 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Celldex Therapeutics NASDAQ:CLDX

$38.24 -0.74 (-1.90%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$38.22 -0.02 (-0.04%)

As of 09/18/2026 07:30 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

uniQure NASDAQ:QURE

$44.00 -0.09 (-0.20%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$44.07 +0.07 (+0.16%)

As of 09/18/2026 07:30 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Arcus Biosciences NYSE:RCUS

$25.30 -0.24 (-0.95%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$25.25 -0.05 (-0.19%)

As of 09/18/2026 07:30 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CADL, QURE, CLDX, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CADL, QURE, CLDX, and RCUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CADL, QURE, CLDX, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL, QURE, CLDX, and RCUS Company Descriptions

Candel Therapeutics NASDAQ:CADL

Celldex Therapeutics NASDAQ:CLDX

uniQure NASDAQ:QURE

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CADL, QURE, CLDX, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CADL, QURE, CLDX, and RCUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CADL, QURE, CLDX, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL, QURE, CLDX, and RCUS Company Descriptions

Candel Therapeutics NASDAQ:CADL

Celldex Therapeutics NASDAQ:CLDX

uniQure NASDAQ:QURE

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools